OverviewJanuary 2022

2

National Cancer CenterLeading nation’s cancer treatment, prevention, control programs, research and education

1962 established by Ministry of Health and Welfare (MHLW*1) as the first National Center for Advanced and Specialized Medical Care (followed by five more)

2010 designated “Incorporated Administrative Agency*2”

2015 appointed “National Research and Development Agency *3”

*1 MHLW: currently Ministry of Health, Labour and Welfare*2 Public Service Entity*3 Highest Ranked Research Organization

3

Milestones

1962Ministry of Health and Welfare establishesNational Cancer CenterHospital starts operating

1992 Establishes NCC Hospital East

2004 Establishes Research Centerfor Cancer Prevention and Screening

2005 Establishes Research Centeron Innovative Oncology

2006 Establishes Center for Cancer Controland Information Services

2010 Becomes Incorporated Administrative Agency

2012 Establishes Exploratory Oncology Research &Clinical Trial Center (EPOC)

2015 Appointed National Research andDevelopment Agency

2016Establishes Center for Research Administration andSupport/ Center for Cancer Registries

2017Establishes Cancer Metabolome Research Centerin Yamagata PrefectureEstablishes Center of New Surgical and Endoscopic Development for Exploratory Technology (NEXT)

2021

Establishes Center for Cancer Genomics andAdvanced Therapeutics (C-CAT)

History of Cancer Control

1964 National Strategy: 5 Pillars of Cancer Control

1984 Comprehensive 10-year Strategy for Cancer Control

1994 New 10-year Strategy to Overcome Cancer

2004 3rd-term Comprehensive Ten-year Strategy for Cancer Control

2005 Action Plan 2005

2006 Cancer Control Act

2007 Basic Plan to Promote Cancer Control Programs

2012 2nd Basic Plan to Promote Cancer Control Programs

2013 Cancer Registration Promotion Act

2014 10-year Strategy of Cancer Research

2015 AMED starts Japan Cancer Research Project

2017 3rd Basic Plan to Promote Cancer Control Programs

2018 3rd Basic Plan to Promote Cancer Control Programs

2018

Establishes Institute for Cancer Control (ICC)

4

Vision and Mission

VisionNCC is committed to providing the best possible cancer treatment and care in partnership with communities

Mission• Discover the fundamental causes of cancer, towards early diagnosis

and prevention • Promote innovation in diagnosis and treatment • Establish and make available the most advanced standard of care to

all patients • Explore and support patients with the best “cancer survivorship” • Garner cancer information and disseminate to society • Develop talent • Advocate policies • Contribute globally, working with international partners

Prevent, overcome, with and beyond cancer

5

NCC Organization

Number of Staff: 3913（April 2021）

President

HospitalTsukiji

Hospital EastKashiwa

EPOCExploratory OncologyResearch & Clinical

Trial Center

Kashiwa

ICCInstitute for Cancer

Control

Tsukiji

C-CATCenter for Cancer

Genomicsand Advanced Therapeutics

Tsukiji

Research Institute

Tsukiji

• Executive Advisers to President• Strategic Planning Bureau• Center for Research Administration and Support• Center for Promotion of Translational Research• Education and Professional Career Development Bureau• IT Integrating and Support Center• Office for Advanced Medical Care Evaluation & Health Technology Assessment• Practical Research for Innovative Cancer Control Management Office• Administrative Departments• Compliance Office• Research Audit Section• Library

Auditors

President’s Offices

Audit office

Directors’ Meeting

Board of Directors

Headquarters for Cancer Information Services

Japan Health Research Promotion Bureau

6

Hospital, Tsukiji campus

‐Neurosurgery and Neuro-Oncology‐Ophthalmic Oncology‐Head and Neck Surgery‐Head and Neck, Esophageal Medical Oncology ‐Plastic and Reconstructive Surgery‐Breast Surgery‐Medical Oncology‐Thoracic Surgery‐Thoracic Oncology‐Esophageal Surgery‐Gastric Surgery‐Colorectal Surgery‐Gastrointestinal Medical Oncology‐Endoscopy‐Hepatobiliary and Pancreatic Surgery‐Hepatobiliary and Pancreatic Oncology‐Urology‐Gynecology

Clinical management, Education, Research, Safety management, Business management

‐Outpatient Treatment Center‐Endoscopy Center‐Appearance Support Center‐Rare Cancer Center‐Interventional Radiology Center‐Patient Flow Support Center‐Genetic Medicine and Services-Cellular Therapy Processing‐Innovation Center for Supportive, Palliative and Psychosocial Care

‐Cancer Screening Center‐Clinical Laboratories‐Surgical Center‐Clinical Engineering and MedicalTechnology

-Radiation Safety and Quality Assurance

‐Clinical Ethics‐Nutrition Management‐Infectious Diseases-Medical Informatics‐Pharmacy ‐Nursing‐ Radiological Technology‐ Clinical Research Support‐ International Clinical Development

Director Deputy Directors

Clinical departments

Dept. of Medical Affairs

Research Audit Section

Ethical Review Support Section

Dept. of Safety Management

‐Musculoskeletal Oncology and Rehabilitation

‐Dermatologic Oncology‐Hematology‐Hematopoietic Stem Cell Transplantation‐Pediatric Oncology‐Pediatric Surgery‐ Dentistry‐General Internal Medicine‐Anesthesia and Intensive Care‐Palliative Medicine‐Psycho-Oncology‐Diagnostic Radiology‐Radiation Oncology‐Diagnostic Pathology-Laboratory Medicine‐Experimental Therapeutics

Specialist departments

Center for Education and Professional Career Development

Total Quality Management Center

7

Hospital, Tsukiji campus578 beds, 246 Staff Doctors, 144 Resident Doctors, 671 Nurses (April 2021)

• 1400 patients/day(new and returning)• Out-patient treatment center• (69 beds): chemotherapy for 186

patients/day• High precision radiation therapy

Out-patient• 17 operation rooms; 5100 operations/annum• Advanced endoscopic surgery for early gastric cancer

EMR endoscopic mucosal resection ESD endoscopic submucosal dissection

• Cutting-edge Interventional radiology with 2 Angio-CT systems• Hematopoietic Stem Cell Transplant• Palliative Medication and Patient Support• Hospital based clinical trials and research

In-Patient• High-precision screening with spiral-

CT, PET (positron emission tomography)• 1,600 screenings/annum

Cancer Screening Services

Endoscopy therapeutic roomBuilt-in wiring ceiling system

Cyber KnifeOut-patient Treatment Center 2 Appearance Support CenterRare cancer hotline Consultation, Counseling andSupport Service Center

8

Hospital East, Kashiwa campus

Surgical Device Innovation Office

Clinical and Business management, Education, Research, Safety management

Director Deputy Directors

Ethical Review Support Section

Quality Management Section

Collaboration Support Office

Center for Education and Professional Career Development

NEXT Medical Device Innovation Center

‐Outpatient Treatment Center-Endoscopy Center‐Supportive Care Center-Medical Concierge Promotion Office-Ladies Center

‐Rare Cancer Center‐Clinical Research Support Office‐Genetic Medicine and Services‐Nursing‐Pharmacy‐Clinical Laboratories

‐Head and Neck Surgery‐Head and Neck Medical Oncology‐Plastic and Reconstructive

Surgery‐Breast Surgery‐Medical Oncology‐Thoracic Surgery‐Thoracic Oncology‐Esophageal Surgery‐Gastric Surgery

Clinical departments

‐Colorectal Surgery‐Gastrointestinal Oncology‐Gastroenterology and Endoscopy‐Hepatobiliary and Pancreatic Surgery‐Hepatobiliary and Pancreatic Oncology-Urology‐Gynecology‐Musculoskeletal Oncology -Rehabilitation

Specialist departments

‐Hematology‐Pediatric Oncology -Dentistry‐General Internal Medicine,

Cardiovascular Medicine‐Anesthesiology‐Intensive Care Medicine‐Palliative Medicine‐Psycho-Oncology Service‐Diagnostic Radiology‐Radiation Oncology‐Pathology and ClinicalLaboratories

‐Experimental Therapeutics

‐Radiological Technology‐Medical Informatics-Data Science-Office of Cancer Registry‐Surgical Center‐Clinical Engineering and Medical Technology

‐Radiation Safety and Quality Assurance

-Rehabilitation‐Nutrition Management Office-Social Worker ‐Certified Nurse Curriculum

Dept of Medical Affairs

Research Audit Section

Endoscopic Device Innovation Office

Dept of Safety Management

Research Administration Section

Section of Medical Assistant Management

9

Hospital East, Kashiwa campus425 beds (25 palliative) ,155 Staff Doctors, 116 Resident Doctors, 540 Nurses (at 1 April 2021)

Proton treatment facility Supportive care center

• Laparoscopic/robotic surgery, minimal invasive treatments i.e., ESD• Largest scale outpatient center, pharmacist consultations• First proton treatment facility in Japan, high precision radiology treatment

Leading Edge Care • Abundant experience in early clinical trials and translational research

• New surgical procedures/endoscopic equipment development research – collaboration with academia

Therapeutics Development

Palliative care wards Center of New Surgical and Endoscopic Development for Exploratory Technology

Ladies center

Outpatient Center Hotline

• For patients/family for both physical and mental wellbeing and social life, starting from diagnosis

• Specialist care for female cancer patients/families• First palliative care ward in national hospital, close collaboration with

communities

Holistic Support

10

Research Institute

Fundamental Innovative Oncology Core

Director

‐Molecular Pathology‐Cellular Signaling‐Cancer Biology

Cancer Development and Progression

‐Central Animal Division-Central RadioisotopeDivision

Research Support Core

Deputy Director

‐Cancer Pathophysiology‐Cancer Therapeutics

Translational Research

-Hematological Malignancy-Cancer Stem Cell-Cancer Differentiation

Research of Molecular Functions and Targets

‐Molecular Pharmacology‐Rare Cancer Research‐Cancer Immunology‐Medical AI Research and Development

Frontier Science

‐Epigenomics‐Cancer Genomics‐Genome Biology-Brain Tumor Translational

Research-Molecular Oncology-Genome Analysis Platform

Development-Bioinformatics-Genomic Medicine

Development of Molecular Diagnostics&Individualized Therapy

‐Translational Oncology‐Pharmacology and

Therapeutics-Cancer Model Development

Drug Development & Disease Model Core

‐Biobank and TissueResources

Bioresources Core

‐Clinical Genomics-Proteomics‐Bioinformatics

Omics Core‐Analytical Pathology‐Immune Medicine

Pathology & Immunology Core

11

Largest cancer research centerin Japan, with 455 research staff

Research Institute

139 adjuncts, 239 visiting fellows/invited scholars(April 2021)

1960’s to 1990’s• Heterocyclic amines (food-born carcinogens) discovery• PCR-SSCP method development (citations 3,000+)• Chromosome 21 map completion, AML1 identification, causative gene

of leukemia

Recently• elucidated international collaborative research on carcinogenesis

mechanism utilizing genetic analysis• discovered novel diagnostic markers with large-scale metagenomic

analysis of intestinal bacteria• developed biomarkers to predict clinical impact of immune

checkpoint inhibitors• developed synthetic lethality-based treatment• discovered RET fusion oncogene drug resistance mechanism• developed integrated cancer medical system with AI

Major Accomplishments

Drug Development & Disease Model Core

Pathology & Immunology Core

Omics Core

Bio-resources Core

12

FIOC: Bridging the gap,between preclinical and clinical

• Cell line (November 2020)• Self-made 485 lines

• Animal model (November 2020)• Transplanted model• Produced PDX model 561 lines• Organoid modelsEstablished first Clinical Sequencing

laboratory in Japan

Work with academia/industry in research/drug development

Develop original organoid oranimal models

Support animal & humanbiological experiments

Research Institute

Research Support Core < Bio-resources core > (March 2021)• 91,461 cases of genomic testable

blood/tissue samples• 27,733 cases of pathological material

with clinical information

EPOC Hospital Hospital East

Fundamental InnovativeOncology Core (FIOC)

FIOC

13

EPOC (Exploratory Oncology Research & Clinical Trial Center)

Experimental AnimalsSupport of Animal Experimentation

Director

Functional ImagingRadiation Oncology and Particle Therapy

Boron Neutron Capture TherapyScience and Technology for EndoscopySurgical Technology

Innovative Diagnostic &Therapeutic Device

Psycho-Oncology

Developmental TherapeuticsPathology

Cancer Immunotherapy

Supportive Care Research

Innovative Cancer Treatment

Biomarker Discovery

Translational InformaticsTranslational Genomics

Cancer Immunology

Clinical Pharmacology & TR

Translational Research

Innovative Pathology and Laboratory Medicine

Experimental TherapeuticsClinical Research

Strategic Programs

Core FacilitiesCollaborate Research and Development

14

Working with academia and industry SCRUM-Japan Enrollment

No.

Lung cancer 5,159

non-sq NSCLC 4,383

Squamous 776

GI cancers 5,740

Esophagus 369

Gastric 1,141

Small intestine 93

Colorectal 2,788

HCC 67

Biliary tract 418

Pancreas 652

NET 75

GIST 79

Others 60

Total 10,899

(Feb 2015 – Mar 2019)

15

ICC (Institute for Cancer Control)

Supportive Care, Survivorship and Translational Research

Epidemiology

Prevention

Screening Assessment and Management

Screening Technology

Biostatistical Research

Healthcare Delivery, Survivorship and Policy Research

Cancer Registries

Groups Divisions

Cohort Research

Director

Deputy Director

Health Services Research

Comprehensive Research Planning

and Promotion

Surveillance and Policy Evaluation

Behavioral Sciences

Bioethics and Healthcare Law

International Health Policy Research

Cancer Information Service

Quality Assurance Programs

Supportive Care and Survivorship Research

Prevention and Screening Research

Comprehensive Prevention

Platform and Common Research

Cancer Control Services

16

Work with society, derive evidence to drive cancer control, deliver to all

Institute for Cancer Control

Cancer Prevention Studies• Etiology, epidemiological cohort studies, for healthy life extension• D & I (dissemination and implementation) approach

Early Cancer Detection Research• Developing and establishing cancer screening methods• Building screening efficacy evidence base• Developing screening guidelines by assessing their efficacy, improving

management via quality control, and increasing participation rate

Research for Patients, towards a more fulfilling life• Studies for QOL improvement of cancer survivors and their families, recurrence

prevention, supportive treatment, and community/workforce re-entry• Studies towards improving support for cancer survivors

Research Infrastructure• biostatistics, health sociology, clinical economics and bioethics.

Cancer Control & Information Services • National/hospital-based cancer registry management and analyses ,cancer

information services and consultation services network• National cancer services network support and Evidence based policy support

Penetrate the needs of society leading to prompt and appropriate information dissemination and policy proposals. Maximize the results of our activities by team building among researchers

17

Center for Cancer Genomics and Advanced Therapeutics (C-CAT)

Approvals of:• off-label use• Accelerated approval• IIT within network

Clinical info

Incl.AI analyses

Discovery of novel drugs/biom

arkers

Knowledge database

(CKDB)

Repository Database (genomic and clinical)

Cooperative Hospitals for Cancer Genomic Medicine Expert Panel

Core/Designated Hospitals

Sharing and research use of cancer genomics data

"CKDB findings" with clinical annotations

Certified laboratories for genomic testing

Control quality and advance cancer genomic diagnosis:

Accumulate clinical and genomic information of Japanese cancer patients, establish a database optimized to serve the populaceProvide support to Expert Panels at Designated Core Hospitals for Cancer Genomic MedicineCommunicate genomic medicine-related information with the public, and advocate policy underpinned by nation-wide statistics of cancer genomic medicine

Lead data sharing:

Promote data sharing among designated and cooperative hospitals of cancer genomic medicine following appropriate protocol, and promote cancer care covered by national healthcare insurance

Promote clinical trials, research and development:

Establish data utilization as foundation for clinical trials including investigator-initiated trials, and for drug/device development and precision medicine for cancer patients

Conduct research, nurture talent in preparation for the introduction of Whole Genome Sequencing to health care

1 2 3 4

Mission

18

World’s Best Specialized Hospitals on Oncology

The National Cancer Center Hospital and National Cancer Hospital East were selected as one of the “World’s Best Specialized Hospital s in 2021 and 2022.

The ranking is based on by 40,000 specialist medical professionals from more than 20 countries, which were then validated by a global expert board. Newsweek partnered with Statista to support the World’s Best Hospital Project. The ranking features the top 250 hospitals for oncology.

Special Functioning Hospital• Designated by MHLW as a hospital for patients who require highly advanced medical treatment referred from general hospitals

Clinical Research Core Hospital• Authorized by MHLW as leading hospitals in promoting clinical research and investigator-initiated IND/IDE trials of high international

standard, with the objective of developing Japan’s medical sector through the advancement of innovative drugs, devices, and technology.

Designated Core Hospital for Cancer Genomic Medicine• Designated by MHLW as key medical institution that conducts genetic testing for cancer and various other diseases and selects

appropriate therapies, also involved in research and new drug development and developing human resources working in the field ofcancer and genomic medicine.

Designated Cancer Care Hospital• Designated by MHLW and taking the leadership among 405 hospitals to train physicians and other medical personnel and hold liaison

councils of prefectural base hospitals for cancer treatment leading to the improvement of cancer treatment in Japan as a whole.

National Institute for Childhood Cancers• Designated by MHLW as one of two institutions that provides information (childhood and AYA generation cancers), improve childhood

cancer registries (support for hospital-based cancer registries), personnel training (core training for counsellors who specialize in cancer, employees who carry out hospital-based cancer registries).

19

Accreditations

20

NCCJ Publications and Citations

(2) Comparison with Japanese Academia（2015 –2020）

(1) Publications and citations (June 2021)Year 2015 2016 2017 2018 2019 2020 Total

Total publication including review articles (articles only) 695 (642) 789 (734) 844 (777) 828 (766) 1,072 (988) 1,292 (1,188) 5,520 (5,095)

Citation (articles only) 26,968 (25,037) 29,685 (27,376) 29,027(26,507) 18,888 (17,595) 11,488 (10,247) 5,254 (4,940) 121,310 (111,702)

└ Highly cited (articles only) 31 (29) 28 (22) 39 (34) 35 (33) 49 (43) 36 (33) 218 (194)

Impact factor 15+ (articles only) 53 (49) 69 (66) 77 (68) 64 (62) 69 (64) 104 (94) 436 (403)

Scores calculated from Incites, Clarivate Analytics

Articles in ESI (Clinical Medicine & Multidisciplinary) HCP articles in ESI (Clinical Medicine & Multidisciplinary)

National Cancer Center

National Cancer Center

Clarivate announces the world's top 1% cited publications in comparison to those published in the same year and field as Highly Cited Paper (HCP), announcing the numbers by affiliated institutes. The above charts exhibit articles / HCP with other research institutes in Japan. Although Clarivate Analytics analyzes the number of articles including reviews, the charts figures are limited to articles.

21

NCC and the nationwidecancer care network

National Cancer Center ---2Prefectural Designated Cancer Care Hosps—51District designated Cancer Care Hosps---351Other designated Hosps ---47

Nationwide clinical support network with prefectural + district-designated 451 cancer care hospitals

Clinical trials Cancer registries Consultation and info sharing Palliative care

Prefectural cancer care liaison council

(April 2021)

22

Memoranda of Understanding concluded with:

Overseas Partners

IARC (International Agency for Research on Cancer)

National Cancer Institute, USA

Massachusetts General Hospital

INCa (Institut National Du Cancer)

China-Japan Friendship Hospital

National Cancer Center, PRC

National Cancer Center, Korea

Dharmais Cancer Hospital, Indonesia

Asian Phase 1 ConsortiumChinese University of Hong Kong

National Cancer Center SingaporeNational Taiwan University HospitalSeoul National University Hospital

National Cancer Hospital, Vietnam

National Cancer Institute, Thailand

Ho Chi Minh City Oncology Hospital, Vietnam

Vital Strategies

Tata Memorial Centre, India